BioNTech's Oncology Pipeline Powers a Pivot from Pandemic Profits

BioNTech pivots to cancer, with strong ADC and lung cancer data driving investor optimism. The firm aims for 15 Phase 3 oncology trials by 2026, backed by a €17.2B cash reserve.

BioNTech SE is navigating a critical transition, channeling resources from its fading COVID-19 vaccine windfall into a formidable oncology pipeline. Recent clinical data across multiple cancer types is bolstering investor confidence that the German biotech can evolve into a broad-based cancer specialist. The stock gained nearly 7% last week, closing at €84.70, as the market digested a series of promising updates.

A key driver is the company's antibody-drug conjugate (ADC) program. In a Phase 2 trial for endometrial cancer, the candidate trastuzumab pamirtecan demonstrated an objective response rate of nearly 48%. This starkly outperforms the approximate 15% rate seen with standard chemotherapy in similar settings. BioNTech and its partner DualityBio plan to submit a Biologics License Application (BLA) to the U.S. FDA for this asset later this year. The candidate, for which BioNTech paid $170 million upfront in 2023, already holds Fast Track designation.

Beyond ADCs, lung cancer treatments are a central pillar of the strategy. The company is advancing 16 clinical trials across various lung cancer indications, including four pivotal Phase 3 studies. Early Phase 3 results for the candidate gotistobart showed a 54% reduction in the risk of death compared to standard therapy. In a significant new collaboration, BioNTech is teaming up with Boehringer Ingelheim and Bristol Myers Squibb to test a combination therapy against advanced small cell lung cancer. Early Phase 2 data for one component, pumitamig, showed a 100% disease control rate and a 76.3% objective response rate. Patient recruitment for the combined study is slated to begin in the second half of 2026.

Wall Street is taking note of this clinical momentum. Bank of America raised its price target on the U.S.-listed shares to $130. The median analyst price target stands at approximately $133, with the majority of the 18 covering analysts maintaining a Buy rating. Only Leerink Partners strikes a more cautious note with a "Market Perform" assessment.

Financially, the company is well-capitalized to fund this ambitious shift, sitting on a cash pile of roughly €17.2 billion. This war chest is essential as it weathers a projected revenue decline. Management forecasts a roughly 25% drop in 2026 sales to between €2.0 and €2.3 billion, down from last year's €2.9 billion, as the firm operates deeply in the red.

The technical picture presents a mixed signal. The share price of €84.70 hovers near its 50-day moving average of €84.45 but remains about 20% below its 52-week high of €105.90. It recently failed to break through the more significant 200-day line.

Looking ahead, BioNTech has set an ambitious goal of having 15 active Phase 3 studies in oncology by the end of 2026. The planned BLA for its HER2-ADC and the initiation of the new lung cancer combination study, both targeted for 2026, are the most immediate catalysts. Shareholders will also convene for a virtual Annual General Meeting on May 15, 2026, where they will vote on the allocation of a retained earnings balance of €6.9 billion. The company's ability to execute on its clinical timelines will ultimately determine whether its stock can realize the significant upside analysts currently project.